In: Clinical & Experimental Metastasis, 2015, vol. 32, no. 7, p. 677-687
|
In: Plos one, 2013, vol. 8, no. 7, p. e68863
Immunogen design for HIV-1 vaccines could be based on epitope identification of naturally occurring neutralizing antibodies in infected patients. A tier 2 neutralizing monoclonal antibody (mAb), HJ16 recognizes a new epitope in the CD4 binding site (CD4bs) region that only partially overlaps with the b12 epitope. We aimed to identify the critical binding site by resistance induction in a...
|
In: Plos one, 2011, vol. 6, no. 10, p. e25488
Several new human monoclonal antibodies (mAbs) with a neutralizing potential across different subtypes have recently been described. Three mAbs, HJ16, HGN194 and HK20, were obtained from patients within the HIV-1 cohort of the Institute of Tropical Medicine (ITM). Our aim was to generate immunization antibodies equivalent to those seen in plasma. Here, we describe the selection and...
|
In: Plos one, 2010, vol. 5, no. 1, p. e8805
Background The isolation of human monoclonal antibodies (mAbs) that neutralize a broad spectrum of primary HIV-1 isolates and the characterization of the human neutralizing antibody B cell response to HIV-1 infection are important goals that are central to the design of an effective antibody-based vaccine. Methods and Findings We immortalized IgG+ memory B cells from individuals infected with...
|
In: Naturwissenschaften, 2006, vol. 93, no. 9, p. 426-430
|
In: Parasitology, 1989, vol. 98, no. S1, p. S49-S60
|
In: International Immunology, 1991, vol. 3, no. 6, p. 587-597
|
In: Clinical Infectious Diseases, 2003, vol. 36, no. 8, p. 990-995
|
In: Journal of Medical Entomology, 2012, vol. 49, no. 6, p. 1226-1232
|
In: Clinical Infectious Diseases, 2008, vol. 46, no. 2, p. 223-231
|